Genetic variants that cause rare disorders may remain elusive even after expansive testing, such as exome sequencing. The diagnostic yield of genome sequencing, particularly after a negative ...

The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 ...

We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...

Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and ...

Introducing a new RNA-seq platform for intracellular multimodal profiling that could transform cancer research and ...

Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Cancer Immunology, Immunotherapy ...

This image illustrates the typical steps in next-generation sequencing (excluding single-molecule sequencing methods). The process begins with isolating genomic DNA (a) and breaking it into short ...